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Abstract
Transmissible spongiform encephalopathies often are caused by peripheral uptake of infectious prions,
and the peripheral nervous system is involved in prion spread to the brain. Although the cellular prion
protein is subjected to fast axonal transport, the mechanism of intranerval transport of infectious prions
is unclear. Here we administered prions intranervally to transgenic mice overexpressing the four-repeat
human tau protein, which exhibit defective fast axonal transport. These mice showed unaltered
neuroinvasion, suggesting that transport mechanisms distinct from fast axonal transport effect prion
neuroinvasion along peripheral nerves. Surprisingly, scrapie-sick tau transgenic mice accumulated
intraneuronal deposits of hyperphosphorylated tau protein. The coincidence of tau and prion pathology
resembled Gerstmann-Sträussler-Scheinker syndrome. These findings identify tau pathology as a
possible end stretch of prion-induced neurodegeneration.
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Transmissible spongiform encephalopathies often are caused
by peripheral uptake of infectious prions, and the peripheral
nervous system is involved in prion spread to the brain. Al-
though the cellular prion protein is subjected to fast axonal
transport, the mechanism of intranerval transport of infectious
prions is unclear. Here we administered prions intranervally to
transgenic mice overexpressing the four-repeat human tau pro-
tein, which exhibit defective fast axonal transport. These mice
showed unaltered neuroinvasion, suggesting that transport
mechanisms distinct from fast axonal transport effect prion
neuroinvasion along peripheral nerves. Surprisingly, scrapie-
sick tau transgenic mice accumulated intraneuronal deposits of
hyperphosphorylated tau protein. The coincidence of tau and
prion pathology resembled Gerstmann–Stra¨ussler–Scheinker
syndrome. These findings identify tau pathology as a possible
end stretch of prion-induced neurodegeneration.
Key words: transmissible spongiform encephalopathy; prion
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Prion diseases are transmissible fatal neurodegenerative diseases
occurring in genetic, infectious, and sporadic forms (Prusiner,
1991; Aguzzi et al., 2001). Although the infectious agent is
propagated most efficiently via intracerebral inoculation, periph-
eral infection is the natural route of transmission in many prion
diseases. A large body of evidence suggests that the lymphore-
ticular system (LRS) as well as the peripheral nervous system
(PNS) are important for neuroinvasion (Lasmezas et al., 1996;
Klein et al., 1997). Intraperitoneal inoculation of the infectious
agent initially results in lymphatic prion accumulation and repli-
cation (Eklund et al., 1967; Kimberlin and Walker, 1986). Follic-
ular dendritic cells (FDC), which express cellular prion protein
(PrPC) and for which the maturation depends on lymphotoxin
-mediated signals, may be necessary for prion replication and
may be important for neuroinvasion (Fraser et al., 1996; Brown et
al., 1999; Montrasio et al., 2000; Klein et al., 2001). On the other
hand, several studies have shown that neuroinvasion can be
achieved in mice for which the LRS does not express PrPC (Race
et al., 2000) and, in certain instances, even in mice that do not
contain mature FDCs (Prinz et al., 2002). Finally, adoptive bone
marrow transfer of PrPC-expressing cells into PrP knock-out
mice results in the accumulation of prions in lymphoid organs,
but not in the transport of prions to the brain, indicating that a
nonhematopoetic PrPC-expressing tissue compartment is re-
quired for efficient neuroinvasion (Bla¨ttler et al., 1997; Kaeser et
al., 2001).
Transport along peripheral nerves to the CNS was suggested by
the finding that intranerval (i.n.) injection of prions bypasses the
need for extraneural replication of the infectious agent (Kimber-
lin et al., 1983). Both the parasympathetic (Beekes et al., 1998)
and the sympathetic nervous systems (Glatzel et al., 2001) appear
to be involved in neuroinvasion. Whether axonal or nonaxonal
mechanisms of transport underlie the progression of the infec-
tious agent within the nervous system remains to be elucidated.
Whereas PrPC was shown to be subjected to fast axonal transport
(Borchelt et al., 1994), the transport of PrPSc has been investi-
gated so far only indirectly, by comparing the incubation times of
mice inoculated intraneurally, extraneurally, and intracerebrally
(Kimberlin et al., 1983; Glatzel and Aguzzi, 2000).
Fast axonal transport is a microtubule-dependent mechanism
in which tau, a member of microtubule-associated proteins known
to stabilize microtubules, plays an important role (Mandelkow
and Mandelkow, 1995). Here we show that transgenic mice with
a defect in fast axonal transport attributable to the overexpression
of the four-repeat tau protein isoform under a neuron-specific
promoter (thy-1.1-tau) (Spittaels et al., 1999) do not exhibit
prolonged incubation times after intranerval inoculation with
prions when compared with control mice, suggesting that mech-
anisms distinct from fast axonal transport effect prion neuroinva-
sion along peripheral nerves. Surprisingly, thy-1.1-tau mice
showed abundant deposits of hyperphosphorylated tau protein at
advanced stages of prion disease, reminiscent of the neuropatho-
logical lesions observed in Gerstmann–Stra¨ussler–Scheinker dis-
ease (GSS).
MATERIALS AND METHODS
Measurement of axonal transport in vivo. Retrograde fast axonal transport
in thy-1.1-tau transgenic mice was studied by injecting 0.5 l of Texas
Red-labeled dextran (stock concentration 50 mg/ml, molecular weight
70,000, lysine-fixable, diluted 1:1 in PBS; Molecular Probes, Leiden, The
Netherlands) in the sciatic notch of transgenic and control animals. For
intranerval injections the mice were anesthetized with xylazine/ket-
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amine, and the left sciatic nerve was exposed surgically by dislodging the
gluteus superficialis muscle and the biceps femoris muscle. The nerve
was placed onto a metal plate (20  5  0.5 mm), and 0.5 l of Texas
Red-labeled dextran was injected with a 34-gauge Hamilton syringe over
a period of 2 min. To increase the efficiency of uptake, we gently
squeezed the injected nerve with a microsurgical forceps (Vercelli et al.,
2000). The nerve was repositioned anatomically, and the skin was closed
with USP 4.0 nylon sutures. Six control mice and six tau transgenic mice
were anesthetized with xylazine/ketamine and perfused transcardially
with 2% paraformaldehyde/PBS [1 hr (n  8) or 3 hr (n  2) after
injection]. Injected (ipsilateral) and noninjected (contralateral) sciatic
nerves were isolated and postfixed for 10 sec in 2% paraformaldehyde/
PBS; a 1 mm segment, located 10 mm proximally to the injection site, was
fiber teased, embedded in fluorescent mounting medium (Dako,
Glostrup, Denmark), and stored protected from light. Fluorescent vesi-
cles were quantified via a fluorescence microscope (excitation filter,
530–585 nm) linked to a digital camera (Zeiss, AxioCam 072, Axiovision
Software). Axons containing fluorescent vesicles were counted as posi-
tive; axons from the noninjected side served as negative controls. Addi-
tional negative controls included one mouse injected with dextran in-
tranervally after transection of the injected nerve proximally to the
injection site and mice killed immediately before (n  1) or after (n  1)
dextran injection. We transformed the data logarithmically and analyzed
them in a one-tailed Student’s t test ( p  0.01).
Measurement of axonal transport in vitro. We performed time-lapse
recordings of fluorescently labeled vesicles in axons from cultured dorsal
root ganglia (DRGs) isolated from thy-1.1-tau transgenic mice and from
control mice. For this, DRGs were isolated from postnatal day 0 (P0) to
P3 mice and kept in culture for 5–11 d in DMEM/F-12 medium (In-
vitrogen, San Diego, CA) supplemented with L-glutamine (Invitrogen),
1% penicillin /streptomycin (Invitrogen), 10% fetal calf serum (Fluka,
Buchs, Switzerland), sodium pyruvate (cfin  1 mM; Invitrogen), and
NGF (cfin  10 ng/ml; Sigma, Deisenhofen, Germany). Endocytotic
uptake of fluorescent dextran was achieved by incubating DRGs for 30,
45, 50, or 60 min with medium containing fluorescent dextran (cfin  0.1
mg/ml, 70,000 MW, lysine-fixable; Molecular Probes). Cells were washed
twice and transferred to a microscope chamber with phenol red-free
NGF growth medium supplemented with horseradish peroxidase (HRP;
cfin  200 g/ml), glucose oxidase (cfin  200 g/ml), glucose (cfin  25
mM), and hemoglobin (cfin 1–4 mg/ml). Analysis of fluorescent vesicles
was performed according to established protocols (Nakano and Greber,
2000). The velocities of anterogradely and retrogradely transported ves-
icles were calculated if they were identifiable for at least 20 frames in a
series and represented the mean of all average velocities of vesicles
transported toward the nucleus or the cell periphery. Fluorescent vesicles
with velocities 0.1 m/sec were disregarded to exclude movements
caused by Brownian motion, which produces trajectories with a variety of
random patterns. The numbers of individual vesicle steps were obtained
by tracing individual vesicles moving faster than 0.1 m/min (n  70 for
controls; n  48 for thy-1.1-tau). The calculated data of transport veloc-
ities were analyzed with a one-tailed Student’s t test ( p  0.01).
Thin section electron microscopy. DRGs isolated from control mice (15
d in cell culture) were incubated with HRP (175 U/mg, 10 mg/ml in NGF
growth medium; Sigma) at 37°C for 15 min, washed, and fixed in 2%
glutaraldehyde/PBS for 20 min at room temperature. HRP activity was
visualized by incubating DRGs with 0.5 mg/ml diaminobenzidine (DAB;
Sigma) in 0.05 M Tris-HCl, pH 7.4 (Sigma), containing 0.01% hydrogen
peroxide (Fluka) for 10 min; embedding and thin section electron mi-
croscopy (TEM) analysis of cells were performed according to estab-
lished protocols (Suomalainen et al., 1999).
Scrapie inoculation. After anesthesia with xylazine/ketamine, the con-
trol and thy-1.1-tau mice were inoculated with a 1% (1 l, i.n.) or 0.001%
(30 l, i.c.) brain homogenate prepared as described previously (Bu¨eler
et al., 1993) from mice infected with the Rocky Mountain Laboratory
scrapie prions (RML 4.1) or with similarly prepared brain homogenate
from uninfected mice (mock). Intranerval injections were performed as
described for dextran injections. Inoculated mice were checked every
third day. Scrapie was diagnosed according to standard clinical signs.
Infectivity bioassays. Homogenates of DRGs (2.5% in 0.32 M sucrose)
and sciatic nerves (10% in 0.32 M sucrose) derived from terminally
scrapie-sick control and tau transgenic mice were prepared by homoge-
nizing the tissues with a pellet mixer (TreffLab), followed by sonication
(Branson 450 for 5 min; constant output power, 400 W). Then 30 l
(diluted 1:10 in PBS and 1% BSA) of homogenates was inoculated
intracerebrally in four tga20 mice (Fischer et al., 1996) by using a 300 l
syringe (Becton Dickinson, Heidelberg, Germany). Incubation times
until the development of terminal scrapie disease were determined, and
infectivity titers were calculated (Prusiner et al., 1982) by using the
relationship: y  11.45  0.088 x, where y is LD50 and x is the incubation
time (days) to terminal disease (Brandner et al., 1996b).
Western blot analysis. Homogenates (10%, w/v) of brain and spleen
were prepared as described previously (Bu¨eler et al., 1993) and, where
indicated, digested with 20 g/ml proteinase K for 30 min at 37°C. Then
50 g (brain) or 100 g (spleen) of total protein was electrophoresed
through a 12%-SDS polyacrylamide gel, transferred to a nitrocellulose
membrane (BA 85, 0.45 m pore size; Schleicher & Schuell, Dassel,
Germany), probed with antibody ICSM18 (1:20,000), and developed by
enhanced chemiluminescence (Amersham Biosciences, Braunschweig,
Germany). Quantification of un-, mono-, and diglycosylated PrP Sc was
accomplished by scanning the membranes with a Kodak image station 440.
Histolog ical studies. Brains from selected mice were fixed with 4%
buffered formalin, inactivated for 1 hr with 98% formic acid, and em-
bedded in paraffin. Sections of 3 m thickness were subjected to con-
ventional staining and to immunostaining to glial fibrillary acidic protein
(GFAP; Dako) and hyperphosphorylated tau (AT8 and AT270, Innoge-
netics, Gent, Belgium) according to standard protocols. Selected sections
were silver impregnated according to the Bielschowsky and Gallyas
protocol.
For quantification of hyperphosphorylated tau deposits, AT270-
positive axonal spheroids were counted in consecutive step sections of
the brainstem (n  10; distance, 25 m) in sex and age-matched mock-
inoculated tau transgenic (n  4), terminally scrapie-sick tau transgenic
(n  4), and wild-type (n  2 for mock; n  2 for terminally scrapie-sick)
mice. Counting was performed independently by two blinded research-
ers. The number of tau spheroid-containing neurons, averaged for each
mouse, was analyzed statistically by the one-tailed Student’s t test ( p 
0.05).
RESULTS
Impaired axonal transport in tau transgenic mice
Previous morphological studies of thy-1.1-tau mice suggested a
defect in fast axonal transport (Spittaels et al., 1999). This was
studied in more detail, visualizing fast axonal transport of fluo-
rescent dextran in vivo and in vitro. Quantification in a nerve
segment located 10 mm proximally to the intranerval injection
site demonstrated a significant decrease of fluorescent vesicles in
tau transgenic mice [number of vesicles per unit area (n/a) 0.90]
when compared with controls (n/a  1.58; p  0.01) at 1 hr after
injection. However, the quantification of fluorescent vesicles at 2
hr (n/a 1.16 for tau; n/a 1.68 for controls) or 3 hr (n/a 1.69
for tau; n/a  1.57 for controls) after dextran injection did not
show any significant differences between transgenic and control
nerves.
In an attempt to substantiate the in vivo data, we undertook in
vitro experiments by taking advantage of cultured transgenic and
wild-type DRGs. Incubation with fluorescent dextran resulted in
strictly axonal transport of fluorescent vesicles, as evidenced by
TEM of HRP-treated DRGs (Fig. 1A).
Time-lapse fluorescent microscopy enabled us to study both
retrograde and anterograde vesicle transport in real time (Fig.
1A–F, time-lapse video sequence, available at a www.jneuro-
sci.org). For control DRGs 5255 individual vesicle steps (n  1199
retrograde; n  1032 anterograde) and for tau-DRGs 5292 vesicle
steps (n  753 retrograde; n  610 anterograde) were traced.
Statistical analysis revealed a significant reduction in the relative
velocities of vesicles (i.e., the proportion of vesicles with any veloc-
ity 0.1 m/min) in both retrograde and anterograde vesicle
transport of DRGs that expressed transgenic tau. In contrast, the
calculated mean of absolute velocities of fluorescent vesicles mov-
ing faster than 0.1 m/min revealed that both retrograde and
anterograde vesicle transport did not differ significantly between
transgenic (48 traced vesicles resulting in 0.2 m/sec for retro-
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grade and 0.184 m/sec for anterograde transport) and control
mice (70 traced vesicles resulting in 0.21 m/sec for anterograde
and 0.196 m/sec for retrograde transport; p  0.05; one-tailed
Student’s t test). These results are consistent with the finding that
the motility of vesicles in transgenic DRGs (25.93%) is reduced
compared with control DRGs (42.16%).
Unhampered prion transport in peripheral nerves of
tau transgenic mice
To determine whether the observed axonal transport defect of tau
transgenic mice might decrease the efficiency of prion neuroinva-
sion along peripheral nerves, we inoculated tau transgenic (n 8)
and control mice (n  8) intranervally with prions (4 logLD50).
All animals developed scrapie at similar time points; therefore,
expression of the transgene did not elicit any significant delay
until the onset of terminal scrapie disease. The mean incubation
time for tau transgenic mice was 222 d  37.89 and 201.6 d 
30.41 for wild-type controls (Fig. 2). None of the mock-inoculated
tau transgenic (n  4) and control mice (n  4) developed
scrapie, and all were killed after 451 d. The severity of patholog-
ical lesions (spongiosis and gliosis) in tau and control mice was
similar (Fig. 3).
Biochemical analysis of proteinase K-resistant PrPSc in brains
and spleens by Western blotting demonstrated similar levels of
PrPSc in transgenic and control mice (Fig. 4). Analysis of the
glycotype patterns (Collinge et al., 1996) of tau and control mice
did not reveal significant differences (data not shown). Mock-
inoculated mice contained native PrPC in brain and spleen, but
no proteinase K-resistant PrPSc (Fig. 4).
No differences in scrapie incubation time of
intracerebrally injected mice
Several studies have suggested a possible interaction of hyper-
phosphorylated tau protein with PrPC or PrPSc resulting in vari-
Figure 1. Visualization of fast axonal transport. A–F, Recordings of fluorescent vesicles in thy-1.1-tau DRGs 15 min after dextran incubation. A single
fluorescent vesicle (arrow) was traced in 153 subsequent frames. Shown are frames 7, 17, 103, 123, and 153. Scale bar, 10 m. A more intuitive
representation is available for download as a complete time-lapse video sequence at www.jneurosci.org. G, Transmission electron microscopic picture
showing intra-axonal localization of HRP (arrow; original magnification, 30,000). H, I, Density blots of traced vesicles in transgenic (H ) and wild-type
( I ) DRGs display an asymmetrical shape and show only a slight vertical extension, indicating microtubule-dependent transport rather than random
movement.
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ations in disease progression or clinical presentation (Ghetti et
al., 1996; Tranchant et al., 1997; Brown, 2000). To investigate this
in more detail and to exclude any transport-unrelated effects on
the incubation time of scrapie in tau transgenic mice, we inocu-
lated both groups of mice intracerebrally with prions (3.5
logLD50). We were not able to detect differences until the onset of
terminal scrapie in mice inoculated with prions intracerebrally.
Incubation times were 148.5 d  1.73 for tau transgenic (n  4)
and 150.33 d 2.89 for control mice (n 4) (Fig. 3). Histological
analysis did not reveal differences in the degree of gliosis and
spongiosis between transgenic and control mice.
Unaltered prion titers in sciatic nerves and DRGs of
tau transgenic and control mice
Infectivity titers of specific portions of the PNS were examined by
bioassay. Calculated prion titers in sciatic nerves and DRGs of
thy-1.1-tau and control mice were similar (3.2 and 3.1 logLD50 
gm1 for control sciatic nerves; 4.2 and 3.8 logLD50  gm
1 for
thy-1.1-tau sciatic nerves; 4.0 and 3.2 logLD50 gm
1 for control
DRGs; and 4.2 logLD50 gm
1 for thy-1.1-tau DRGs) (Fig. 2C).
PrPSc induces accumulation of hyperphosphorylated
tau protein
In certain human prion diseases the accumulation of PrPSc is
accompanied by the accumulation of hyperphosphorylated tau
protein (Ghetti et al., 1996; Brown, 2000). A recent publication
highlighted the possibility that protein–protein interactions might
be involved in abnormal tau protein accumulation (Go¨tz et al.,
2001). We therefore studied whether the accumulation of PrPSc
observed in terminally scrapie-sick mice might induce a similar
phenomenon in tau transgenic mice. Quantitative analysis re-
vealed a significantly (t test; p  0.05) larger number of hyper-
phosphorylated tau-containing axonal spheroids per brainstem
section (n  10) in terminally sick thy-1.1-tau transgenic mice
Figure 2. Survival plots of prion-inoculated mice. Incubation time (days)
until terminal scrapie after administration of 4 logLD50 scrapie prions
intranervally (A) and 3.5 logLD50 intracerebrally (B) to thy-1.1-tau trans-
genic mice and control mice. Incubation times were similar in the two
groups. C, Infectivity levels in ipsilateral sciatic nerve (scn ip) of thy-1.1-
tau transgenic mice (dark diamonds), controls (lighter diamonds), ipsilat-
eral dorsal root ganglia (drg ip) of thy-1.1-tau transgenic (dark square), and
control mice (lighter squares). Each symbol represents one individual
assayed mouse; error bars reflect the variability of the infectivity bioas-
says. Prion titers are indicated in logLD50 units per milliliter.
Figure 3. Histopathological findings in hippocampi of mice. Hematoxy-
lin and eosin-stained (A, C, E, G) and GFAP-stained (B, D, F, H ) brain
sections of thy-1.1 tau (C, D, G, H ) and control mice (A, B, E, F ) after
intranerval inoculation of scrapie prions (E–H) and mock inoculum
(A–D). Spongiform changes and intense, diffuse gliosis were visible in
brains of infected thy-1.1-tau and control mice. Scale bar, 50 m.
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(n  4) compared with age-matched noninfected thy-1.1-tau
transgenic mice (n  4) (Fig. 5). The presence of hyperphospho-
rylated tau in thy-1.1-tau transgenic mice was confirmed by using
the phosphorylation-dependent antibody AT8. No hyperphospho-
rylated tau containing axonal spheroids was observed in mock-
inoculated and terminally scrapie-sick wild-type mice.
DISCUSSION
Numerous publications have demonstrated the importance of the
PNS for prion neuroinvasion (Kimberlin et al., 1983; Beekes et
al., 1998; Race et al., 2000). These studies have contributed
significantly to our current understanding of prion neuroinvasion
along peripheral nerves: the favored model proposes that PrPC
expression on the PNS is essential for efficient neuroinvasion
(Bla¨ttler et al., 1997; Glatzel and Aguzzi, 2000; Race et al., 2000)
and that prion neuroinvasion occurs mainly along nerve fibers
belonging to the sympathetic and the parasympathetic nervous
systems (Beekes et al., 1998; Glatzel et al., 2001).
In contrast, relatively little is known about the molecular de-
tails of PrPSc transport within or along peripheral nerves. Axonal
transport mechanisms are conceivable, including passive slow
axonal transport and ATP-driven fast axonal transport, and even
nonaxonal modes of transport. Determination of the velocity of
PrPSc movement within peripheral nerves by comparing incuba-
tion times of mice inoculated in distal or proximal parts of the
PNS suggested slow axonal transport for PrPSc (Kimberlin et al.,
1983). Conversely, in vitro studies showing fast axonal transport
for PrPC (Borchelt et al., 1994) led to the hypothesis that PrPSc
might be transported in a similar manner. Alternatively, nonax-
Figure 4. Western blot detection of PrP C and PrP Sc. Top blot, Extracts
of brain; bottom blot, extracts of spleen. Genotypes of mice, route of
inoculation, and proteinase K digest are indicated above each lane. For
control, we analyzed terminally sick, intracerebrally inoculated CD1 mice
(control ), and mock-injected wild-type mice (mock). The amounts of total
protein loaded in each lane were 50 g for brain and 100 g for spleen.
PrP Sc, defined by the appearance of three partially protease-resistant
immunoreactive bands (corresponding to unglycosylated, mono-, and
diglycosylated forms of the prion protein), was readily detectable in brains
and spleens of thy-1.1-tau and control mice.
Figure 5. Histological analysis demon-
strating deposition of abnormally phos-
phorylated tau protein. Shown are
brainstem (A, C) and nucleus olivaris
accessorius dorsalis (B, D) of terminally
scrapie-sick thy-1.1-tau (A, B) and age-
matched noninfected thy-1.1-tau mice
(C, D). Sections are stained with the
phosphorylation-dependent anti-tau an-
tibody AT270, showing significantly in-
creased accumulation of pathological
tau in scrapie-sick thy-1.1-tau mice (B)
when compared with controls (D). E,
AT270-positive tau deposits in the brain-
stem of scrapie-sick (prion-inoculated,
lef t four lanes) and age-matched control
mice (mock-inoculated, right four lanes)
were counted in 10 standardized brain-
stem sections. Each column represents
one individual mouse. A statistically sig-
nificant increase of abnormal tau depos-
its was observed in scrapie-sick thy-1.1-
tau mice (Student’s t test; p  0.05).
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onal modes of transport for PrPSc have been put forth by a
number of studies. The proposed mode of transport encompasses
the membrane-bound progression of PrPSc along axons and
Schwann cells in a domino manner (Brandner et al., 1996a;
Glatzel and Aguzzi, 2000).
We decided to investigate peripheral prion transport in trans-
genic mice with defective axonal transport. The exact nature of
this transport defect, which is caused by overexpression of the
four-repeat human tau protein, has been described only indirectly
(Spittaels et al., 1999). The results of in vivo and in vitro experi-
ments substantiate previous morphological findings and confirm
that overexpression of this human tau isoform results in impaired
axonal transport. Furthermore, we were able to specify the exact
nature of this defect as impairment of anterograde and retro-
grade fast axonal transport. The sequential events underlying the
cause of this defect are unknown; an excess of tau protein may (1)
prevent the initial attachment of proteins by competing for bind-
ing sites on the microtubules, (2) reduce the transport capacity of
motor proteins by blocking the microtubule network, or (3) re-
duce the binding efficiency of vesicles to motor proteins.
Transgenic and appropriate control mice were then inoculated
intranervally or intracerebrally with prions. We were not able to
detect a significant difference in the incubation time until the
onset of terminal scrapie disease, and the titers of infectious
prions were similar in sciatic nerves and DRGs of transgenic and
control mice.
Two conclusions can be drawn from the analysis of these data.
First, transport of infectious prions exploits, in contrast to PrPC
(Borchelt et al., 1994), mechanisms distinct from fast axonal
transport. This is in accordance with previous studies (Brandner
et al., 1996a; Glatzel and Aguzzi, 2000) and raises the possibility
that infectious prions might be transported via noncanonical
mechanisms, e.g., in a domino-like manner along PrPC-
expressing nerve membranes. Sciatic nerves and DRGs of tau
transgenic and control mice contained substantial amounts of
infectious prions when assayed at the terminal stage of scrapie,
indicating that affected nerves may function not only as conduits
but also as reservoirs of the agent. If, conversely, prions were
transported strictly in vesicles moving retrogradely, one would
expect only the transient presence of infectious prions in affected
nerves.
On the other hand, the moderate impairment of fast axonal
transport observed in tau transgenic mice may not be sufficient to
evoke drastic changes in scrapie incubation times. We feel that
this is unlikely, because the incubation time after challenging with
a defined inoculum is extremely sensitive to perturbations of
pathogenesis.
Transgenes often display significant variegation of expression
(Robertson et al., 1995); if fast axonal transport were blocked only
in a small fraction of the relevant neurons, the above conclusions
would be less strong. This was studied in detail earlier, and no
evidence for strong variegation of expression of the tau transgene
was found (Spittaels et al., 1999, 2000).
The entirely unexpected finding that the accumulation of pri-
ons leads to enhanced production of hyperphosphorylated tau
protein in tau transgenic mice, but not in wild-type mice, has
several important implications.
First, it may result from yet unidentified protein–protein inter-
actions between PrPSc and tau. Such interactions may be direct or
may be part of an “amyloid cascade,” analogous to the finding that
neurofibrillary tangle formation is augmented by intracerebral
administration of recombinant -amyloid in tau transgenic mice
(Go¨tz et al., 2001). This could explain why neurodegenerative
conditions like Alzheimer’s or Creutzfeldt–Jakob disease are
associated with a pathological accumulation of various proteins,
including tau and A, a finding that was interpreted as epiphe-
nomenological in some studies (Hainfellner et al., 1998).
Second, the observed neuropathological features are highly
reminiscent of GSS disease, indicating that prion-inoculated thy-
1.1-tau mice are the first viable mouse model for this entity. The
generation of mouse models for GSS was attempted both by
transgenesis and by injecting synthetic PrP, yet the essential
features of this disease, like the deposition of abnormal tau
protein, could not be achieved (Manson et al., 1999; Kaneko et
al., 2000). Prion-injected thy-1.1-tau mice will be useful for the
study of temporal and spatial aggregation of PrPSc and hyper-
phosphorylated tau protein and might help to understand the role
of tau aggregation in GSS disease (Ghetti et al., 1994).
In conclusion, this study provides insights in the transport of
PrPSc along peripheral nerves and strengthens the notion that
prions are not transported by any of the conventional axonal
cargo systems. Additionally, scrapie-sick tau transgenic mice show
pathological and biochemical features reminiscent of GSS dis-
ease, implying that these mice represent a useful model of this
entity.
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